Sutro Biopharma (NASDAQ:STRO) Shares Down 4.8% – Time to Sell?

Posted by George Bondi on Jul 11th, 2026

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report)’s stock price fell 4.8% during trading on Thursday . The company traded as low as $30.23 and last traded at $30.31. 93,071 shares changed hands during trading, a decline of 63% from the average daily volume of 250,598 shares. The stock had previously closed at $31.84.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Leerink Partners set a $43.00 price target on Sutro Biopharma and gave the stock an “outperform” rating in a report on Friday, May 15th. Deutsche Bank Aktiengesellschaft increased their price objective on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Friday, May 8th. Mizuho set a $50.00 target price on shares of Sutro Biopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. Finally, Citigroup reissued an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sutro Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $52.44.

View Our Latest Stock Analysis on STRO

Sutro Biopharma Price Performance

The company’s 50-day moving average is $31.20 and its 200-day moving average is $23.88. The firm has a market capitalization of $492.63 million, a price-to-earnings ratio of -2.69 and a beta of 1.51.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. Sell-side analysts anticipate that Sutro Biopharma, Inc. will post -9 earnings per share for the current year.

Institutional Trading of Sutro Biopharma

Institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new position in shares of Sutro Biopharma in the 1st quarter worth $17,818,000. Bank of America Corp DE increased its stake in Sutro Biopharma by 348.1% during the first quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock worth $470,000 after acquiring an additional 14,661 shares during the last quarter. Stempoint Capital LP acquired a new stake in Sutro Biopharma during the first quarter worth about $580,000. ADAR1 Capital Management LLC raised its holdings in shares of Sutro Biopharma by 681.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after purchasing an additional 457,364 shares during the period. Finally, Orbimed Advisors LLC purchased a new position in shares of Sutro Biopharma in the 1st quarter worth about $19,956,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.